title: Phase I study of antilipopolysaccharide human monoclonal antibody MAB-T88.
abstract: Monoclonal antibody MAB-T88 is a human monoclonal immunoglobulin M antibody directed at the lipopolysaccharide of gram-negative bacteria. In this study, nine patients who were expected to become neutropenic from antineoplastic chemotherapy received an infusion of MAB-T88, three patients at each of three doses: 1, 4, and 8 mg/kg of body weight. MAB-T88 was shown to be safe, with an effective half-life in plasma of 25.4 h, and no patient developed immunoglobulin G antibody to MAB-T88.
authors.affiliation: Chiron Corporation, Emeryville, California 94608-2997.
authors.forename: R
authors.initials: R
authors.lastname: Daifuku
authors.forename: K
authors.initials: K
authors.lastname: Haenftling
authors.forename: J
authors.initials: J
authors.lastname: Young
authors.forename: E S
authors.initials: ES
authors.lastname: Groves
authors.forename: C
authors.initials: C
authors.lastname: Turrell
authors.forename: F J
authors.initials: FJ
authors.lastname: Meyers
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D006207:Half-Life; D006801:Humans; D007136:Immunoglobulins / Q000276:immunology*; D007262:Infusions, Intravenous
chemical_list: D000911:Antibodies, Monoclonal; D007136:Immunoglobulins; C042866:antilipopolysaccharide antibodies